Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Friday session in red amid volatile trading. The shares closed down -0.66 points or -1.52% at $42.88 with 3,206,109 shares getting traded. Post opening the session at $43.08, the shares hit an intraday low of $42.70 and an intraday high of $43.22 and the price vacillated in this range throughout the day. The company has a market cap of $102.71 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
GlaxoSmithKline plc (ADR) (GSK) on Sept. 14, 2016 nnounced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix™, showing 90% efficacy in adults aged 70 years and older that is maintained for at least four years. The results were published in the New England Journal of Medicine (NEJM).
The study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old. Vaccine efficacy was maintained across the various age groups included in the study, ranging between 90% in people aged 70-79 years (95% confidence interval: 83-94%) and 89% in those aged 80 years and above1(95% confidence interval: 74-96%).
The high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%). A pooled analysis of data from both trials showed the vaccine demonstrated 91% efficacy against shingles (95% confidence interval: 86-95%) in adults aged 70 years and older compared to placebo. This efficacy was maintained with an 88% reduction in the risk of shingles (95% confidence interval: 73-95%) in the fourth year after vaccination.
The risk of serious adverse events, potential immune-mediated diseases or deaths observed in ZOE-70 was similar in people receiving Shingrix and placebo. The most commonly reported local adverse reaction was pain at the injection site and the most frequently reported systemic adverse reaction was fatigue. The majority of injection site and systemic reactions occurred within seven days of vaccination, with most lasting 1-3 days, and generally were mild-to-moderate in intensity.
Shares of Acadia Healthcare Company Inc (NASDAQ:ACHC) ended Friday session in green amid volatile trading. The shares closed up +2.59 points or 5.27% at $51.81 with 3.18 million shares getting traded. Post opening the session at $49.16, the shares hit an intraday low of $49.12 and an intraday high of $51.91 and the price vacillated in this range throughout the day. The company has a market cap of $4.77 billion and the numbers of outstanding shares have been calculated to be 87.42 million shares.
On Sept. 12, 2016 Acadia Healthcare Company Inc (ACHC) and Ochsner Health System have reached a definitive agreement to create a joint venture 82-bed acute psychiatric hospital, serving the greater New Orleans metropolitan area.
“New Orleans is a radically under-bedded market, with long wait lists for care locally. We intend this facility to be a leading regional resource for inpatient psychiatric care,” said Joey Jacobs, Chairman and CEO of Acadia Healthcare.
Under the terms of the agreement, the new facility in LaPlace, LA, will be built in the current location of Ochsner’s River Parishes’ Emergency Room; The E.R. will move into a new building of its own a short distance away. Acadia will provide the investment to reconstruct the building, and handle day-to-day management of the facility.
Joey Jacobs adds: “The new hospital will benefit tremendously with the Ochsner relationship. Ochsner is one of Louisiana’s largest and most trusted hospital systems. This new facility is a perfect complement to our other Acadia facilities in Louisiana. This model follows other recent successful joint venture partnerships in Massachusetts and Memphis.”